CN111848778A - Teriparatide analogues - Google Patents
Teriparatide analogues Download PDFInfo
- Publication number
- CN111848778A CN111848778A CN202010355587.3A CN202010355587A CN111848778A CN 111848778 A CN111848778 A CN 111848778A CN 202010355587 A CN202010355587 A CN 202010355587A CN 111848778 A CN111848778 A CN 111848778A
- Authority
- CN
- China
- Prior art keywords
- teriparatide
- acid
- arg
- analogue
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical class C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 title claims abstract description 100
- 108010049264 Teriparatide Proteins 0.000 claims abstract description 28
- 229960005460 teriparatide Drugs 0.000 claims abstract description 25
- 150000001413 amino acids Chemical group 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 13
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 90
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 84
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 84
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 82
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 64
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 61
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 57
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 53
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 52
- -1 γ -Glu Chemical compound 0.000 claims description 50
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 49
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 48
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 48
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims description 44
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 37
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 36
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 36
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 36
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 36
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 36
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 36
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 34
- 239000004220 glutamic acid Substances 0.000 claims description 34
- 229930182847 D-glutamic acid Natural products 0.000 claims description 33
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 33
- 229940000635 beta-alanine Drugs 0.000 claims description 28
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 28
- 229960002433 cysteine Drugs 0.000 claims description 28
- 235000018417 cysteine Nutrition 0.000 claims description 28
- 235000018977 lysine Nutrition 0.000 claims description 28
- 239000004471 Glycine Substances 0.000 claims description 27
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 27
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 27
- 230000004048 modification Effects 0.000 claims description 27
- 238000012986 modification Methods 0.000 claims description 27
- 229960005261 aspartic acid Drugs 0.000 claims description 26
- 235000003704 aspartic acid Nutrition 0.000 claims description 26
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 26
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 25
- 239000004475 Arginine Substances 0.000 claims description 24
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 24
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 24
- 229960003121 arginine Drugs 0.000 claims description 24
- 235000009697 arginine Nutrition 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000004472 Lysine Substances 0.000 claims description 23
- 239000011616 biotin Substances 0.000 claims description 19
- 229960002685 biotin Drugs 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 17
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 17
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 17
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 17
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 17
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 17
- 239000004473 Threonine Substances 0.000 claims description 17
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 17
- 230000010933 acylation Effects 0.000 claims description 17
- 238000005917 acylation reaction Methods 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 17
- 229960001230 asparagine Drugs 0.000 claims description 17
- 235000009582 asparagine Nutrition 0.000 claims description 17
- 235000020958 biotin Nutrition 0.000 claims description 17
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 17
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 17
- 229960000310 isoleucine Drugs 0.000 claims description 17
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 17
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 17
- 239000004474 valine Substances 0.000 claims description 17
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 16
- 208000001132 Osteoporosis Diseases 0.000 claims description 16
- 229940024606 amino acid Drugs 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 229930182817 methionine Natural products 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 13
- 229960003964 deoxycholic acid Drugs 0.000 claims description 13
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 claims description 9
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 9
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 150000002669 lysines Chemical group 0.000 claims description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- HXMVNCMPQGPRLN-UHFFFAOYSA-N 2-hydroxyputrescine Chemical compound NCCC(O)CN HXMVNCMPQGPRLN-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000000149 penetrating effect Effects 0.000 abstract description 4
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 239000000199 parathyroid hormone Substances 0.000 description 41
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- 102000003982 Parathyroid hormone Human genes 0.000 description 37
- 108090000445 Parathyroid hormone Proteins 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 37
- 102000004196 processed proteins & peptides Human genes 0.000 description 37
- 229960001319 parathyroid hormone Drugs 0.000 description 29
- 238000000034 method Methods 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000011347 resin Substances 0.000 description 18
- 229920005989 resin Polymers 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 239000012071 phase Substances 0.000 description 13
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 12
- 238000002390 rotary evaporation Methods 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000005336 cracking Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000032895 transmembrane transport Effects 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- XQPYRJIMPDBGRW-UHFFFAOYSA-N 2-[2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCCOCCOCC(=O)O)C3=CC=CC=C3C2=C1 XQPYRJIMPDBGRW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000006144 lipoylation Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- BUUKFBVDKSFMHN-LKMAISLMSA-N parathar acetate Chemical compound CC(O)=O.C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 BUUKFBVDKSFMHN-LKMAISLMSA-N 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 229960000338 teriparatide acetate Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WDUQJXKBWRNMKI-UHFFFAOYSA-N 18-[(2-methylpropan-2-yl)oxy]-18-oxooctadecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCC(O)=O WDUQJXKBWRNMKI-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108091006614 SLC10A2 Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 108010012543 amino-terminal parathyroid hormone Proteins 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 108091022863 bile acid binding Proteins 0.000 description 1
- 102000030904 bile acid binding Human genes 0.000 description 1
- 108010053098 biotin receptor Proteins 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000008609 bushi Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- OGBMKVWORPGQRR-UHFFFAOYSA-N forteo Chemical group C=1NC=NC=1CC(C(=O)NC(CC(C)C)C(=O)NC(CC(N)=O)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC(O)=O)C(=O)NC(C(C)C)C(=O)NC(CC=1N=CNC=1)C(=O)NC(CC(N)=O)C(=O)NC(CC=1C=CC=CC=1)C(O)=O)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(N)CO)C(C)C)C(C)CC)CC1=CNC=N1 OGBMKVWORPGQRR-UHFFFAOYSA-N 0.000 description 1
- 229940053641 forteo Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to the field of medicines, and particularly relates to a teriparatide analogue. The invention obtains a new teriparatide analogue by modifying and/or substituting amino acid at 13, 26 and/or 27 positions of the N end of teriparatide, has enhanced cell membrane penetrating capacity, and can be used for oral administration.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a teriparatide analogue.
Background
At present, the incidence of osteoporosis in the elderly population is second to diabetes and senile dementia and leaps the third place of senile diseases, so the development of the medicine for treating osteoporosis is also a hot point of research. The drugs for treating osteoporosis can be mainly classified into the following three types: 1. bone mineralization promoting agents such as vitamin D and calcium preparations; 2. drugs that inhibit bone resorption, such as bisphosphonates, dinolizumab, estrogens, calcitonin, and the like; 3. the medicines for promoting bone formation mainly include parathyroid hormone (PTH) and its analogs, calcium ion receptor antagonists, anti-sclerostin monoclonal antibodies, etc. Among them, parathyroid hormone has become the first choice drug for the treatment of osteoporosis in postmenopausal women.
Parathyroid hormone is a polypeptide consisting of 84 amino acids synthesized, stored and secreted by parathyroid epithelial cells, and has the main physiological functions of promoting bone formation, mobilizing blood calcium into bone, and promoting reabsorption of calcium by renal tubules and gastrointestinal tract, thereby achieving the purpose of treating osteoporosis. When parathyroid hormone PTH (1-84) enters the human body, it is rapidly metabolized into N-terminal PTH (1-34) fragment, which has full physiological activity and can bind to the corresponding specific receptor of the tissue to exert biological effects. PTH (1-34) has been also developed as a drug for the treatment of osteoporosis because it has the same physiological activity as parathyroid hormone.
Teriparatide (trade name Forteo) is a recombinant PTH (1-34) developed by Eli Lilly corporation, usa, approved by the FDA for marketing in 2002, marketed in china in 2013 (futao), the amino acid sequence is H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH, the product is approved for the treatment of postmenopausal women osteoporosis, primary or hypogonadal male osteoporosis patients, and persistent, systemic glucocorticoid-related osteoporosis patients.
The existing teriparatide on the market is an injection, a low-dose intermittent administration mode is adopted, subcutaneous injection is needed to be performed once a day, and great pain is brought to patients. If oral administration of teriparatide can be realized, clinical compliance of patients can be greatly improved.
However, for oral polypeptide drugs, their bioavailability in vivo is low, mainly due to: (1) the complex enzyme environment of the gastrointestinal tract makes the polypeptide easily degraded in the gastrointestinal tract; (2) the molecular weight is large and the adhesive film layer is not easy to pass; (3) lack of lipid solubility, poor permeability and difficulty in entering systemic circulation through small intestinal epithelial cells. The lipophilicity of the polypeptide can be increased by modifying the polypeptide through lipid acylation, so that the polypeptide can enter the systemic circulation through gastrointestinal tract cells. Meanwhile, receptors exist on the surface of gastrointestinal tract cells, and the polypeptide is chemically modified by using a ligand, and the ligand and the receptor realize specific binding so as to facilitate the polypeptide to penetrate the cells, such as cholic acid (sodium ion-dependent bile acid transporter ASBT) and biotin (sodium ion-dependent biotin receptor). In the US9993430B2 patent, the lipophilicity of the polypeptide is increased by carrying out lipid acylation modification on GLP-1, and the oral bioavailability of the GLP-1 polypeptide is improved by the combined action of the polypeptide and a penetration enhancer SNAC; y.w.cho et al/Lancet 2(2012) reports an oral insulin IN-105, wherein a section of PEG-fatty acid amphiphilic side chain is modified on a beta chain Lys29 to increase the lipophilicity of the insulin, thereby realizing the oral administration mode of the insulin; in US20110014247, 5-CNAC is added as a penetration enhancer to form a compound with polypeptide in a non-covalent bond manner, so that the lipophilicity of the polypeptide is increased, and the gastrointestinal permeation of the polypeptide is improved; in US8962015, biotin is used as a target to assist in penetrating the drug-loaded liposome into a single cell layer, so that the bioavailability of oral polypeptide is improved. Increasing cell permeation of polypeptides by increasing lipid solubility has now found widespread use in the field of oral polypeptides, however, chemical modifications may cause changes in the conformation of the polypeptide, resulting in loss of activity of the polypeptide. Therefore, when modifying a polypeptide, it is also critical to maintain the activity of the polypeptide.
Disclosure of Invention
The present patent application relates to teriparatide analogues which are modified and/or substituted with amino acids at position 13, 26 and/or 27 of the N-terminus of teriparatide.
In one aspect, the present application provides teriparatide analogs that are modified at one, two, or three lysines at position 13, 26, and/or 27 of the N-terminus of teriparatide.
In some embodiments, the modification is an acylation modification.
In some embodiments, the modification sites are located at one, two, or three of the three lysines at positions 13, 26, and 27 of the N-terminus of teriparatide.
In some embodiments, the modification site is located at one, two, or three of the three free-amino groups distributed over the three lysines at positions 13, 26, and 27 of the N-terminus of teriparatide.
In some embodiments, the general structural formula of the aliphatic chain for acylation modification of teriparatide is: HOOC- (AEEA)m-(Xaa)n-R1Wherein Xaa is one or more of D-alanine (D-Ala), beta-alanine (beta-Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), D-glutamic acid (D-Glu), gamma-glutamic acid (gamma-Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met) or default. m is one of 0,1,2,3,4 and 5. n is one of 0,1,2 and 3. R 1Is aliphatic straight chain, branched chain C6-C20Deoxycholic acid, biotin or a deletion.
In some embodiments, m is a number from 0,1,2,3,4,5, preferably from 0 to 3, more preferably 2; n is the number 0,1,2,3, preferably 0 or 1, more preferably 1. When n is 1, (Xaa)nIs D-alanine (D-Ala), beta-alanine (beta-Ala), 4-aminobutyric acid (GABA), 2-ammonia(ii) one of isobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), D-glutamic acid (D-Glu), γ -glutamic acid (γ -Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met); preferably 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), D-alanine (D-Ala), beta-alanine (beta-Ala), aspartic acid (Asp), cysteine (Cys), gamma-glutamic acid (gamma-Glu), glycine (Gly), proline (Pro), phenylalanine (Phe); more preferably gamma-glutamic acid (gamma-Glu), proline (Pro). R1Selected from the group consisting of heptanoyl, methylheptanoyl, octanoyl, methyloctanoyl, nonanoyl, methylnonanoyl, decanoyl, methyldecanoyl, lauroyl, myristoyl, palmitoyl, octadecanoyl, 17-carboxyheptadecanoyl, 15-carboxypentadecanoyl, 13-carboxytridecanoyl, 11-carboxyundecanoyl, deoxycholic acid and biotin; preferably lauroyl, myristoyl, palmitoyl, octadecanoyl, 17-carboxyheptadecanoyl, deoxycholic acid, biotin; more preferably, octadecanoyl group and 17-carboxyheptadecanoyl group.
The invention provides teriparatide lipidated derivatives, which have the following structures (polypeptide sequences are in the sequence from N end to C end):
when two or three lysine modifications are present at positions 13, 26 or 27, the T in the modifying group is the same structure, wherein the general chemical structure T can be represented as:
wherein m is a number of 0,1,2,3,4,5, n is a number of 0,1,2,3, p is an integer of 6 to 20, R2is-H or-COOH; xaa is one or more or the default of D-alanine (D-Ala), beta-alanine (beta-Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), D-glutamic acid (D-Glu), gamma-glutamic acid (gamma-Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met).
More specifically, the side chain structure can be represented by the following structural formula:
wherein m is selected from an integer of 0 to 5, preferably an integer of 0 to 2, more preferably 2; xaa 1Selected from the group consisting of D-alanine (D-Ala), β -alanine (β -Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), D-glutamic acid (D-Glu), γ -glutamic acid (γ -Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met); preferably 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), D-alanine (D-Ala), beta-alanine (beta-Ala), aspartic acid (Asp), cysteine (Cys), gamma-glutamic acid (gamma-Glu), glycine (Gly), proline (Pro), phenylalanine (Phe); more preferably gamma-glutamic acid (gamma-Glu), proline (Pro).
In another aspect, the present application provides a class of teriparatide analogs having a substitution of a lysine at position 13, 26 or 27 of the N-terminus of teriparatide, the analogs having the general formula:
H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-X1-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-X2-X3-Leu-Gln-Asp-Val-His-Asn-Phe-OH
wherein, X1,X2,X3Not simultaneously Lys, and X1,X2,X3At least one of which is Lys; in some embodiments, X is 1,X2,X3Any one or two of D-alanine (D-Ala), beta-alanine (beta-Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), D-glutamic acid (D-Glu), gamma-glutamic acid (gamma-Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met), preferably D-alanine (D-Ala), beta-alanine (beta-Ala), 2-aminoisobutyric acid (Aib), arginine (Arg), cysteine (Cys), glycine (Gly), more preferably arginine (Arg).
In another aspect, the present application provides acylated modifications of teriparatide analogues having a substitution of lysine at position 13, 26 and/or 27 of the N-terminus of teriparatide, said analogues having the general formula:
H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-X1-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-X2-X3-Leu-Gln-Asp-Val-His-Asn-Phe-OH
wherein, X1,X2,X3Not simultaneously Lys, and X1,X2,X3At least one of which is Lys; in some embodiments, X is1,X2,X3Either or both of which areOne or two of D-alanine (D-Ala), β -alanine (β -Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), D-glutamic acid (D-Glu), γ -glutamic acid (γ -Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met); preferably D-alanine (D-Ala), beta-alanine (beta-Ala), 2-aminoisobutyric acid (Aib), arginine (Arg), cysteine (Cys), glycine (Gly), more preferably arginine (Arg);
Wherein the acylation modification site is positioned at X1,X2Or X3Lys of (3), further, the acylation site is located at X1,X2Or X3Lys at (a) is free-amino.
In some embodiments, the fatty chain structure for acylation modification is of the general formula: HOOC- (AEEA)m-(Xaa)n-R1Wherein Xaa is one or more of D-alanine (D-Ala), beta-alanine (beta-Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), D-glutamic acid (D-Glu), gamma-glutamic acid (gamma-Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met) or default. m is one of 0,1,2,3,4 and 5. n is one of 0,1,2 and 3. R1Is aliphatic straight chain, branched chain C6-C20Deoxycholic acid, biotin or a deletion.
In some embodiments, m is a number from 0,1,2,3,4,5, preferably from 0 to 3, more preferably 2; n is the number 0,1,2,3, preferably 0 or 1, more preferably 1. When n is 1, (Xaa) nIs D-alanine (D-Ala), beta-alanine (beta-Ala), 4-aminobutyric acid (GABA),2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), D-glutamic acid (D-Glu), γ -glutamic acid (γ -Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met); preferably 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), D-alanine (D-Ala), beta-alanine (beta-Ala), aspartic acid (Asp), cysteine (Cys), gamma-glutamic acid (gamma-Glu), glycine (Gly), proline (Pro), phenylalanine (Phe); more preferably gamma-glutamic acid (gamma-Glu), proline (Pro). R1Selected from the group consisting of heptanoyl, methylheptanoyl, octanoyl, methyloctanoyl, nonanoyl, methylnonanoyl, decanoyl, methyldecanoyl, lauroyl, myristoyl, palmitoyl, octadecanoyl, 17-carboxyheptadecanoyl, 15-carboxypentadecanoyl, 13-carboxytridecanoyl, 11-carboxyundecanoyl, deoxycholic acid and biotin. Preferably lauroyl, myristoyl, palmitoyl, octadecanoyl, 17-carboxyheptadecanoyl, deoxycholic acid, biotin. More preferably, octadecanoyl group and 17-carboxyheptadecanoyl group.
In another aspect, the present application provides an acylated modification of a teriparatide analogue, said modification being represented by the general formula (polypeptide sequence in order from N-terminus to C-terminus):
X2 26,X3 27,Lys13-PTH(1-34)
X1 13,X3 27,Lys26-PTH(1-34)
X1 13,X2 26,Lys27-PTH(1-34)
Wherein, X1Selected from the group consisting of D-Ala, β -Ala, GABA, Aib, Abu, Arg, Asp, Asn, Cys, D-Glu, γ -Glu, Gln, Gly, His, Ile, Leu, Pro, Phe, Ser, Tyr, Thr, Trp, Val, Met, preferably β -Ala, GABA, Aib, Abu, Arg, Cys, more preferably Arg; x2Selected from the group consisting of D-Ala, β -Ala, GABA, Aib, Abu, Arg, Asp, Asn, Cys, D-Glu, γ -Glu, Gln, Gly, His, Ile, Leu, Pro, Phe, Ser, Tyr, Thr, Trp, Val, Met, preferably β -Ala, GABA, Aib, Abu, Arg, Cys, more preferably Arg; x3Selected from the group consisting of D-Ala, β -Ala, GABA, Aib, Abu, Arg, Asp, Asn, Cys, D-Glu, γ -Glu, Gln, Gly, His, Ile, Leu, Pro, Phe, Ser, Tyr, Thr, Trp, Val, Met, preferably β -Ala, GABA, Aib, Abu, Arg, Cys, more preferably Arg;
wherein, the chemical structural general formula T can be represented as:
wherein m is a number of 0,1,2,3,4,5, n is a number of 0,1,2,3, p is an integer of 6 to 20, R2is-H or-COOH; xaa is one or more or the default of D-alanine (D-Ala), beta-alanine (beta-Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), D-glutamic acid (D-Glu), gamma-glutamic acid (gamma-Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met).
More specifically, the side chain structure T can be represented by the following structural formula:
wherein m is selected from 0-5, preferably 0-2, more preferably 2; xaa1Selected from the group consisting of D-alanine (D-Ala), β -alanine (β -Ala), 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib), 2-aminobutyric acid (Abu), arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), D-glutamic acid (D-Glu), γ -glutamic acid (γ -Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), phenylalanine (Phe), serine (Ser), tyrosine (Tyr), threonine (Thr), tryptophan (Trp), valine (Val), methionine (Met); preferably 4-aminobutyric acid (GABA), 2-aminoisobutyric acid (Aib) D-alanine (D-Ala), beta-alanine (beta-Ala), aspartic acid (Asp), cysteine (Cys) gamma-glutamic acid (gamma-Glu), glycine (Gly), proline (Pro), phenylalanine (Phe); more preferably gamma-glutamic acid (gamma-Glu), proline (Pro).
In some embodiments, the present application provides acylated modifications of a class of teriparatide analogs selected from compounds having the following structure (polypeptide sequences in order from N-terminus to C-terminus):
1.N-27-PTH(1-34)-AEEA-AEEA-Pro-C17-COOH:
2.N-13-PTH(1-34)-AEEA-AEEA-α-Glu-C16:
3.N-26-PTH-γ-Glu-C12:
4.N-27-PTH (1-34) -AEEA-deoxycholic acid:
5.N-13-(Arg26,Gly27)PTH(1-34)-γ-Glu-C16:
6.N-27-(Arg13,Arg26)PTH(1-34)-AEEA-Gly-AEEA-Gly-γ-Glu-C17-COOH:
7.N-26-(Cys13,Ala27)PTH(1-34)-Phe-AEEA-AEEA-AEEA-C12:
8.N-26-(Arg13,Arg27)PTH(1-34)-AEEA-AEEA-C11-biotin:
9.N-27-(Arg13,Arg26)PTH(1-34)-AEEA-AEEA-C17-COOH:
10.N-27-(Arg13,Arg26)PTH(1-34)-AEEA-Glu-C17-COOH:
11.N-27-(Arg13,Arg26)PTH(1-34)-AEEA-AEEA-Ala-C17-COOH:
12.N-27-(Arg13,Arg26)PTH(1-34)-AEEA-AEEA-C16:
compared with teriparatide, the in vitro bioactivity of the teriparatide analogue in the application is not changed greatly, the bioactivity of the polypeptide cannot be influenced by modifying the side chain, and the polarity is obviously reduced, in reverse chromatography, the elution ratio of the acetonitrile phase of the analogue is increased from 40% to 55% -60% of PTH, which shows that the polarity is reduced after the lipid acylation, thereby being beneficial to realizing transmembrane transport of the polypeptide.
The teriparatide analogue has the advantages that the cell permeability is remarkably improved, the PTH derivative has higher capability of penetrating a monolayer cell layer than a PTH reference substance in an in-vitro Caco-2 cell transmembrane transport experiment, and the apparent permeability coefficient P of the PTH derivativeappThe value is 1.89-4.03 times of that of a PTH standard product, and the modification of lipoylation can effectively enhance the cell membrane penetrating capacity.
In the application, only one lysine is left in the sequence of teriparatide by replacing the amino acid of teriparatide, so that only one modification site for lipoylation is reserved, the purification process is simple, and the purity of the product is improved.
The present application provides pharmaceutically acceptable salts of the aforementioned teriparatide analogs or uses thereof.
The polypeptide related to the application can be used for treating osteoporosis.
The teriparatide analogue can be used as an effective medicinal ingredient of an oral preparation; can also be used as an effective pharmaceutical ingredient for injection, such as intravenous injection, subcutaneous injection, intramuscular injection and the like; can also be used as effective component of topical medicine
The teriparatide analogue can be prepared into a pharmaceutically effective dosage unit by the existing pharmaceutical technology, and the form of the effective dosage unit can be oral administration, tablets, capsules or liquid and other dosage forms.
The teriparatide analogue components of the present application can be formulated in an aqueous formulation wherein the water content is not less than 50%.
In some embodiments, the oral preparation can be in the form of tablets, troches, pills, capsules (e.g., hard capsules, soft capsules, enteric capsules, microcapsules), elixirs, granules, syrups, granules, emulsions, suspensions, solutions, dispersions, and sustained-release preparations for oral or non-oral administration, wherein tablets containing various excipients (e.g., calcium carbonate, calcium phosphate, etc.) can also be formulated as disintegrating preparations.
In some embodiments, the pharmaceutical composition can be released in a controlled manner, including sustained or rapid release, and the controlled release dosage of the relevant pharmaceutical composition can be achieved by known pharmaceutical techniques.
The present application provides a pharmaceutical composition comprising a polypeptide of the present application, or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions of the present application also include a pharmaceutically acceptable excipient, diluent or carrier.
In some embodiments, the pharmaceutical compositions described herein comprise an amount of a teriparatide analog of the present application of at least about 0.1mg, or at least about 0.2mg, or at least about 0.3mg, or at least about 0.4mg, or at least about 0.6mg, or at least about 0.8mg, or at least about 1mg, or at least about 1.5mg, or at least about 2mg, or at least about 2.5mg, or at least about 3mg, or at least about 5mg, or at least about 7mg, or at least about 10mg, or at least about 12mg, or at least about 15mg, or at least about 20mg, or at least about 30mg, or at least about 50mg, or at least about 70mg, or at least about 100 mg.
In some embodiments, the content of the teriparatide analogs of the present application in the pharmaceutical compositions described herein is in the range of 2.5 to 99.4% by weight. In some embodiments, the pharmaceutical composition described herein comprises a teriparatide analog in an amount in the range of 2.5 to 10 weight percent, or in the range of 8 to 15 weight percent, or in the range of 10 to 20 weight percent, or in the range of 15 to 30 weight percent, or in the range of 20 to 40 weight percent, or in the range of 30 to 50 weight percent, or in the range of 40 to 60 weight percent, or in the range of 50 to 70 weight percent.
When used in a treatment for treating osteoporosis, the teriparatide analogs of the present application, in some embodiments, are administered orally at least 100 μ g; in some embodiments, at least 200 μ g is administered orally; in some embodiments, at least 500 μ g is administered orally; in some embodiments, at least 100 μ g is administered orally; in some embodiments, at least 100 μ g is administered orally. When used in therapy for the treatment of osteoporosis, the teriparatide analogs of the present application, in some embodiments, are administered orally in an amount of 20mg or less; in some embodiments, 10mg or less is administered orally; in some embodiments, 5mg or less is administered orally; in some embodiments, 3mg or less is administered orally; in some embodiments, an amount of 2000 μ g or less is administered orally; in some embodiments, an amount of 1000 μ g or less is administered orally. The teriparatide analogs of the present application, when used in therapy for treating osteoporosis, in some embodiments, are administered orally from 200 μ g to 20 mg; in some embodiments, 200 μ g to 10mg is administered orally; in some embodiments, 200 μ g to 5mg is administered orally; in some embodiments, 200 μ g to 3000 μ g is administered orally; in some embodiments, 200 μ g to 2000 μ g is administered orally; in some embodiments, 500 μ g to 1000 μ g is administered orally; in some embodiments, 750 μ g is administered orally.
The teriparatide analogues or pharmaceutical compositions thereof, when used in the treatment of osteoporosis, are administered orally from 1 to 3 times per day according to any of the various embodiments described herein; in some embodiments, the oral administration according to any of the various embodiments described herein is performed 1 or 2 times per day; in some embodiments, the oral administration according to any of the various embodiments described herein is performed 1 time per day.
The scheme of this application still includes:
1. a teriparatide analogue characterized in that said analogue is modified and/or substituted with an amino acid at position 13, 26 and/or 27 of the N-terminus of teriparatide.
2. The teriparatide analogue according to claim 1, which is acylated at position 13, 26 and/or 27 of the N-terminus of teriparatide.
3. The teriparatide analogue of any one of the preceding claims, wherein the acylation modification sites are located at one, two or three of the lysines at position 13, 26 or 27 of the N-terminus of teriparatide.
4. The teriparatide analogue as described in any one of the preceding claims, wherein the fatty chain used for acylation modification has the general structural formula: HOOC- (AEEA)m-(Xaa)n-R1Wherein Xaa is one or more of D-alanine, beta-alanine, 4-aminobutyric acid, 2-aminoisobutyric acid, 2-aminobutyric acid, arginine, aspartic acid, asparagine, cysteine, D-glutamic acid, gamma-glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, proline, phenylalanine, serine, tyrosine, threonine, tryptophan, valine and methionine or is absent; m is a number of 0,1,2,3,4, 5; n is one of 0,1,2 and 3; r 1Selected from aliphatic straight chain and branched chain C6-C20Acyl group of deoxycholic acid, biotin or a deletion.
5. Teriparatide analogues according to any of the preceding claims, wherein m is a number from 0,1,2,3,4,5, preferably from 0 to 3, more preferably 2.
6. Teriparatide analogues according to any of the preceding claims, wherein n is the number 0,1,2,3, preferably 0 or 1, more preferably 1.
7. The teriparatide analogue of any one of the preceding claims, wherein n is 1, said (Xaa)nSelected from 4-aminobutyric acid, 2-aminoisobutyric acid, D-alanine, beta-alanine, aspartic acid, cysteine, gamma-glutamic acid, glycine, prolineAlanine, phenylalanine, preferably gamma-glutamic acid or proline.
8. Teriparatide analogues according to any of the preceding claims, wherein R is1Selected from the group consisting of heptanoyl, methylheptanoyl, octanoyl, methyloctanoyl, nonanoyl, methylnonanoyl, decanoyl, methyldecanoyl, lauroyl, myristoyl, palmitoyl, octadecanoyl, 17-carboxyheptadecanoyl, 15-carboxypentadecanoyl, 13-carboxytridecanoyl, 11-carboxyundecanoyl, deoxycholic acid and biotin, preferably lauroyl, myristoyl, palmitoyl, octadecanoyl, 17-carboxyheptadecanoyl, deoxycholic acid, biotin, more preferably octadecanoyl, 17-carboxyheptadecanoyl.
9. A teriparatide analogue according to any one of the preceding claims, characterised in that the analogue has a structure according to one of the following:
wherein, the chemical structural general formula T can be represented as:
when two or three lysine modifications are present at positions 13, 26 or 27, the T in the modifying group are of the same structure, wherein m is a number from 0,1,2,3,4,5, n is a number from 0,1,2,3, p is an integer from 6 to 20, R is an amino acid residue2is-H or-COOH.
10. The teriparatide analogue according to any one of the preceding claims, characterized in that T may represent the following structure:
wherein m is selected from an integer of 0 to 5, preferably an integer of 0 to 2, more preferably 2; xaa1Selected from the group consisting of D-alanine, beta-alanine, 4-aminobutyric acid, 2-aminoisobutyric acid, 2-aminobutyric acid, arginine, aspartic acid, asparagine, cysteine, D-glutamic acid, gamma-glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, proline, phenylalanine, serine, tyrosine, threonine, tryptophan, valine, methionine; preferably 4-aminobutyric acid, 2-aminoisobutyric acid, D-alanine, beta-alanine, aspartic acid, cysteine, gamma-glutamic acid, glycine, proline, phenylalanine; more preferably gamma-glutamic acid or proline.
11. A teriparatide analogue according to any one of the preceding claims, wherein the analogue has a substitution of a lysine at position 13, 26 or 27 of the N-terminus of teriparatide, the analogue having the general formula:
H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-X1-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-X2-X3-Leu-Gln-Asp-Val-His-Asn-Phe-OH, wherein X1,X2,X3Not simultaneously Lys, and X1,X2,X3At least one of which is Lys.
12. Teriparatide analogues according to any of the preceding claims, characterized in that said X1,X2,X3Any one or two of D-alanine, beta-alanine, 4-aminobutyric acid, 2-aminoisobutyric acid, 2-aminobutyric acid, arginine, aspartic acid, asparagine, cysteine, D-glutamic acid, gamma-glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, proline, phenylalanine, serine, tyrosine, threonine, tryptophan, valine and methionineOne or two of (a); preferably D-alanine, beta-alanine, 2-aminoisobutyric acid, arginine, cysteine, glycine; more preferably arginine.
13. The teriparatide analogue according to any one of the preceding claims, characterized in that the teriparatide analogue is provided with an acylation modification at the site of X1,X2Or X3Lys of (a).
14. The teriparatide analogue according to any one of the preceding claims, wherein the acylation modification is to link an aliphatic chain structure of the general formula: HOOC- (AEEA) m-(Xaa)n-R1Wherein Xaa is one or more of D-alanine, beta-alanine, 4-aminobutyric acid, 2-aminoisobutyric acid, 2-aminobutyric acid, arginine, aspartic acid, asparagine, cysteine, D-glutamic acid, gamma-glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, proline, phenylalanine, serine, tyrosine, threonine, tryptophan, valine and methionine or is absent; m is a number of 0,1,2,3,4, 5; n is one of 0,1,2 and 3; r1Selected from aliphatic straight chain and branched chain C6-C20Acyl group of deoxycholic acid, biotin or a deletion.
15. Teriparatide analogues according to any of the preceding claims, wherein m is a number from 0,1,2,3,4,5, preferably from 0 to 3, more preferably 2.
16. Teriparatide analogues according to any of the preceding claims, wherein n is the number 0,1,2,3, preferably 0 or 1, more preferably 1.
17. Teriparatide analogues according to any of the preceding claims, wherein said n is 1, XaanSelected from 4-aminobutyric acid, 2-aminoisobutyric acid, D-alanine, beta-alanine, aspartic acid, cysteine, gamma-glutamic acid, glycine, proline, phenylalanine, preferably gamma-glutamic acid or proline.
18. Teriparatide analogues according to any of the preceding claims, wherein R is1Selected from the group consisting of heptanoyl, methylheptanoyl, octanoyl, methyloctanoyl, nonanoylExamples of the substituent include a methyl group, a methylnonanoyl group, a decanoyl group, a methyldecanoyl group, a lauroyl group, a myristoyl group, a palmitoyl group, an octadecanoyl group, a 17-carboxyheptadecanoyl group, a 15-carboxypentadecanoyl group, a 13-carboxytridecanoyl group, an 11-carboxyundecanoyl group, a deoxycholic acid group and a biotin group, and the preferable examples are a lauroyl group, a myristoyl group, a palmitoyl group, an octadecanoyl group, a 17-carboxyheptadecanoyl group, a deoxycholic acid group and a biotin group, and the more.
19. A teriparatide analogue according to any one of the preceding claims, characterised in that the analogue has the structure as described below:
wherein, X1Selected from the group consisting of D-Ala, β -Ala, GABA, Aib, Abu, Arg, Asp, Asn, Cys, D-Glu, γ -Glu, Gln, Gly, His, Ile, Leu, Pro, Phe, Ser, Tyr, Thr, Trp, Val, Met, preferably β -Ala, GABA, Aib, Abu, Arg, Cys, more preferably Arg; x2Selected from the group consisting of D-Ala, β -Ala, GABA, Aib, Abu, Arg, Asp, Asn, Cys, D-Glu, γ -Glu, Gln, Gly, His, Ile, Leu, Pro, Phe, Ser, Tyr, Thr, Trp, Val, Met, preferably β -Ala, GABA, Aib, Abu, Arg, Cys, more preferably Arg; x 3Selected from the group consisting of D-Ala, β -Ala, GABA, Aib, Abu, Arg, Asp, Asn, Cys, D-Glu, γ -Glu, Gln, Gly, His, Ile, Leu, Pro, Phe, Ser, Tyr, Thr, Trp, Val, Met, preferably β -Ala, GABA, Aib, Abu, Arg, Cys, more preferably Arg;
wherein, the chemical structural general formula T can be represented as:
wherein m is a number of 0,1,2,3,4,5, n is a number of 0,1,2,3, p is a number of 6-20An integer of (A), R2is-H or-COOH.
20. The teriparatide analogue of any one of the preceding claims, wherein T may be of the structure:
wherein m is selected from an integer of 0 to 5, preferably an integer of 0 to 2, more preferably 2; xaa1Selected from the group consisting of D-alanine, beta-alanine, 4-aminobutyric acid, 2-aminoisobutyric acid, 2-aminobutyric acid, arginine, aspartic acid, asparagine, cysteine, D-glutamic acid, gamma-glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, proline, phenylalanine, serine, tyrosine, threonine, tryptophan, valine, methionine, preferably 4-aminobutyric acid, 2-aminoisobutyric acid, D-alanine, beta-alanine, aspartic acid, cysteine, gamma-glutamic acid, glycine, proline, phenylalanine, more preferably gamma-glutamic acid or proline.
21. Teriparatide analogues according to any of the preceding claims, characterized in that said analogues are selected from compounds having one of the following structures:
1).
22. a pharmaceutical composition comprising any one of the teriparatide analogs or a pharmaceutically acceptable salt thereof.
23. The pharmaceutical composition of any of the preceding claims, further comprising a pharmaceutically acceptable carrier and/or excipient.
24. The pharmaceutical composition according to any one of the preceding claims, which is an injectable formulation or an oral formulation.
25. The pharmaceutical composition according to any one of the preceding claims, wherein the oral formulation is in the form of tablets, troches, pills, capsules, elixirs, granules, syrups, granules, emulsions, suspensions, solutions, dispersions and sustained release formulations for oral or non-oral administration.
26. Use of a pharmaceutical composition according to any of the preceding claims for the manufacture of a medicament for the treatment of osteoporosis.
Definition of
The following terms used in the present application have the following meanings, unless otherwise specified. A particular term should not be considered as ambiguous or unclear without special definition, but rather construed according to ordinary meaning in the art. When a trade name appears herein, it is intended to refer to its corresponding commodity or its active ingredient.
The terms "optionally" or "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, ethyl is "optionally" substituted with halo, meaning that ethyl may be unsubstituted (CH)2CH3) Monosubstituted (e.g. CH)2CH2F) Polysubstituted (e.g. CHFCH)2F、CH2CHF2Etc.) or completely substituted (CF)2CF3). It will be appreciated by those skilled in the art that any group containing one or more substituents will not incorporate any substitution or substitution pattern which is sterically impossible and/or cannot be synthesized.
C as used hereinm-nMeaning that the moiety has m-n carbon atoms. For example, "carbon3-10Cycloalkyl "means the ringThe alkyl group has 3 to 10 carbon atoms. "carbon0-6Alkylene "means that the alkylene group has 0 to 6 carbon atoms, and when alkylene has 0 carbon atom, the group is a bond.
As used herein (AEEA)mOr (Xaa)nRefers to having m or n attached AEEA or Xaa groups in the moiety.
Numerical ranges herein refer to each integer in the given range. E.g. "C1-6By "is meant that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms.
When any variable (e.g., R) occurs more than one time in the composition or structure of a compound, its definition in each case is independent. Thus, for example, if a group is substituted with 2R, then there are separate options for each R.
The term "substituted" means that any one or more of the last hydrogen atoms on a particular atom is replaced with a substituent, so long as the valence of the particular atom is normal and the substituted compound is stable. When the substituent is oxo (i.e., ═ O), meaning that two hydrogen atoms are substituted, oxo does not occur on the aryl.
PTH in the present embodiment refers to PTH (1-34) or analogs having PTH (1-34) as the parent nucleus, unless otherwise specified.
AEEA in the scheme of the invention refers to 8-amino-3, 6 dioxyoctanoic acid.
The term "pharmaceutically acceptable" is intended to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As the pharmaceutically acceptable salt, for example, a metal salt, an ammonium salt, a salt with an organic base, a salt with an inorganic acid, a salt with an organic acid, a salt with a basic or acidic amino acid, and the like can be mentioned. Non-limiting examples of metal salts include, but are not limited to, salts of alkali metals, such as sodium, potassium, and the like; salts of alkaline earth metals such as calcium, magnesium, barium, and the like; aluminum salts, and the like. Non-limiting examples of salts with organic bases include, but are not limited to, salts with trimethylamine, triethylamine, pyridine, picoline, 2, 6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, and the like. Non-limiting examples of salts with inorganic acids include, but are not limited to, salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like. Non-limiting examples of salts with organic acids include, but are not limited to, salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, malic acid, maleic acid, tartaric acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like. Non-limiting examples of salts with basic amino acids include, but are not limited to, salts with arginine, lysine, ornithine, and the like. Non-limiting examples of salts with acidic amino acids include, but are not limited to, salts with aspartic acid, glutamic acid, and the like.
The term "pharmaceutical ingredient" refers to a formulation of one or more compounds of the present application or salts thereof with excipients, diluents, or carriers generally accepted in the art for delivering biologically active compounds to an organism (e.g., a human). The purpose of the pharmaceutical composition is to facilitate administration of the compounds of the present application to an organism.
The term "pharmaceutically acceptable excipient, diluent, or carrier" refers to those excipients, diluents, or carriers that do not significantly irritate the organism and do not impair the biological activity and performance of the active compound. Suitable carriers, diluents and excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble and/or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water and the like.
The present application also includes isotopically-labeled compounds of the present application, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the present application include hydrogen, carbon, nitrogen, oxygen Isotopes of phosphorus, sulfur, fluorine, iodine and chlorine, such as respectively2H、3H、11C、13C、14C、13N、15N、15O、17O、18O、31P、32P、35S、18F、123I、125I and36cl, and the like.
Certain isotopically-labelled compounds of the present application (e.g. with3H and14c-labeled ones) can be used in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Furthermore, substitution with heavier isotopes such as deuterium (i.e. 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g. increased in vivo half-life or reduced dosage requirements) and may therefore be preferred in certain circumstances. Positron emitting isotopes, such as 15O, 13N, 11C, and 18F, can be used in Positron Emission Tomography (PET) studies to determine substrate occupancy. Isotopically labeled compounds of the present application can generally be prepared by following procedures analogous to those disclosed in the schemes and/or in the examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
The compounds of the present application may be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combinations thereof with other chemical synthetic methods, and equivalents thereof known to those skilled in the art, with preferred embodiments including, but not limited to, the examples of the present application.
The chemical reactions of the embodiments herein are carried out in a suitable solvent that is compatible with the chemical changes of the present application and the reagents and materials required therefor. In order to obtain the compounds of the present application, it is sometimes necessary for a person skilled in the art to modify or select the synthesis steps or reaction schemes based on the existing embodiments.
The following examples represent only one aspect of the present invention, and are not intended to limit the subject matter of the invention.
Description of the drawings:
FIG. 1: the teriparatide analogues with amino acid substitutions at positions 13,26 and 27 of PTH (1-34) without acylation modification are shown: (Arg)26,Gly27)Lys13-PTH,(Cys13,Ala27)Lys26-PTH and (Arg)13,Arg26)Lys27In vitro active EC50 value of PTH
The specific implementation scheme is as follows:
example 1N-27-PTH(1-34)-AEEA-AEEA-Pro-C17-COOH
(1) Materials and reagents
2-CTC resin, substitution value 1.15 mmol/g.
The amino acids are: Fmoc-Pro-OH, Fmoc-AEEA-OH, mono-tert-butyl octadecanedioate
Synthesizing a reagent: HOBt, DIC, DMF, DCM, piperidine, DIEA.
(2) Instrument for measuring the position of a moving object
CS-BIO type polypeptide synthesizer, Waters600 semi-preparative high performance liquid chromatograph, Beckman centrifuge, and BUCHI rotary evaporator.
(3) Procedure for the preparation of the
a. Solid phase chemical synthesis of polypeptides
Weighing 1.00g of 2-CTC resin, placing the 2-CTC resin in a reactor of a polypeptide synthesizer, adding 10mLDCM, soaking for 1h, weighing 2-3 times of Fmoc-AEEAc-OH and absorbing 4-6 times of DIEA, adding 10mLDCM, dissolving, putting the mixture into the reactor, reacting at room temperature for two hours, namely, coupling the first amino acid onto the resin, washing the resin for 6 times by DCM, and determining the substitution value (SD) of the resin at the moment; then adding 10ml of 20% PIP/DMF solution, mixing for 30min to remove an amino protecting group, washing the resin with DCM for 6 times, coupling a second amino acid, weighing three times of Fmoc-AEEAc-OH, HOBt and DIC, adding 10ml of DMF/DCM (1:1) mixed solvent for dissolving, reacting, wherein the reaction temperature is room temperature, the reaction progress is monitored by ninhydrin reaction, the reaction is completed when colorless is monitored, and washing the resin with DCM for 6 times. Then, the coupling reaction of proline and octadecanedioic acid can be continued according to the above coupling method, and the process is circulated until all amino acids are coupled.
b. Cracking and precipitation
Adding a cracking reagent according to the ratio of 5mL of the cracking reagent to 1g of resin, stirring and reacting for 1 hour at room temperature according to the ratio of TFE to DCM (1: 4) (V: V), filtering, carrying out rotary evaporation on the filtrate at 40 ℃ until the filtrate is dried, adding 10mLDCM into a rotary evaporation bottle, carrying out rotary evaporation again until the filtrate is dried, repeatedly carrying out the reaction for 2-3 times, finally adding 3mLDCM to dissolve polypeptide, adding 40mL of diethyl ether, placing in a refrigerator at-20 ℃ for 20min, centrifuging, carrying out vacuum drying, and weighing the crude peptide.
c. Preparation of teriparatide derivatives by liquid phase reaction
The dried crude peptide was weighed to about 0.1mmol, HOSU to about 0.095mmol, and DIC 15. mu.L, added to about 5mL tetrahydrofuran, reacted at room temperature for 1-2 hours, rotary evaporated, and THF removed to give a yellow oil. Adding TFA: H2And (3) carrying out tert-butyl ester removal protection in a mixed solvent of O-90: 10, reacting at room temperature for 1 hour, then pouring into glacial ethyl ether for precipitation, centrifuging to obtain a solid, washing with ethyl ether for three times, drying under reduced pressure to obtain solid powder, weighing, and dissolving with DMF to obtain a side chain activated ester solution.
Dissolving 0.5mmol of teriparatide in 0.1mol/L triethylamine solution, slowly dropwise adding a side chain activated ester solution into the solution, wherein the feeding ratio is 1: 1.2, the reaction mixture was stirred at room temperature for 10 minutes, and the pH was adjusted to 8.0 with 0.1mol/L hydrochloric acid to terminate the reaction.
The crude product was purified by semi-preparative RP-HPLC.
1 purification of
A chromatographic column: nano Micro C18 preparation column (10 mm. times.250 mm,10 μm)
Flow rate: 5ml/min
Detection wavelength: 215nm
Mobile phase: phase A: 1% HAC/water solution
Phase B: 1% HAC/acetonitrile
Gradient elution procedure as in table 3:
TABLE 3 gradient elution Table
Analysis of the collected product by Agilent 1260HPLC
A chromatographic column: YMC-pack ODS-AQ C18 analytical column (4.6 mm. times.250 mm,5 μm)
Flow rate: 1ml/min
Detection wavelength: 215nm
Mobile phase: phase A: 0.1% TFA/water
Phase B: 0.1% TFA/acetonitrile
Gradient elution procedure as in table 4:
TABLE 4 gradient elution Table
Collecting target components with the purity of more than 90%, removing acetonitrile by rotary evaporation, and carrying out vacuum freeze drying. The molecular weight is confirmed by ESI-MS, and M/Z is 1201.62 [ M +4H ]+In line with the theoretical molecular weight.
Example 2N-13-PTH(1-34)-AEEA-AEEA-α-Glu-C16
The procedure was as described in example 1, and the molecular weight was confirmed by ESI-MS, M/Z-1194.6 [ M +4H ]+Is consistent with the theoretical molecular weight.
Example 3: n-26-PTH(1-34)-γ-Glu-C12
The procedure was as described in example 1, and the molecular weight was confirmed by ESI-MS, M/Z-1108.2 [ M +4H ]+Is consistent with the theoretical molecular weight.
Example 4: n-27-PTH (1-34) -AEEA-AEEA-deoxycholic acid
The procedure was as described in example 1, and the molecular weight was confirmed by ESI-MS, M/Z-1196.5 [ M +4H ]+Is consistent with the theoretical molecular weight.
Example 5: n-13-(Arg26,Gly27)PTH-γ-Glu-C16
(1) Materials and reagents
2-CTC resin, substitution value 1.15 mmol/g.
Teriparatide analogues (Arg)26,Gly27) PTH is obtained by expression of engineering bacteria or chemical synthesis method, M/Z1019.2 (M +4H)+
The amino acids are: Fmoc-gamma-Glu-Otbu, palmitic acid
Synthesizing a reagent: HOBt, DIC, DMF, DCM, piperidine, DIEA.
(2) Instrument for measuring the position of a moving object
CS-BIO type polypeptide synthesizer, Waters600 semi-preparative high performance liquid chromatograph, Beckman centrifuge and bushi rotary evaporator.
(3) Procedure for the preparation of the
a. Solid phase chemical synthesis of polypeptides
Weighing 1.00g of 2-CTC resin, placing the 2-CTC resin in a reactor of a polypeptide synthesizer, adding 10mLDCM, soaking for 1h, weighing 2-3 times of Fmoc-gamma-Glu-OH and absorbing 4-6 times of DIEA, adding the mixture into 10mLDCM, dissolving, putting the mixture into the reactor, reacting for two hours at room temperature (preferably 25 ℃ or above, or prolonging the reaction time), namely, coupling the first amino acid onto the resin, then washing the resin for 6 times by DCM, and determining the substitution value (SD) of the resin at the moment; then adding 10ml of 20% PIP/DMF solution, mixing for 30min to remove an amino protecting group, washing the resin with DCM for 6 times, coupling a second amino acid, weighing three times of palmitic acid, HoBT and DIC, adding 10ml of DMF/DCM (1:1) mixed solvent together for dissolving, carrying out reaction, wherein the reaction temperature is room temperature, the reaction progress is monitored by ninhydrin reaction, and the reaction is completed when colorless is monitored, and washing the resin with DCM for 6 times.
b. Cracking and precipitation
After the synthesis of the polypeptide is finished, the wet weight is weighed. Adding a cracking reagent according to the ratio of 5mL of the cracking reagent to 1g of resin, stirring and reacting for 1 hour at room temperature, filtering to a 25mL rotary evaporation bottle, carrying out rotary evaporation at 40 ℃ until no liquid exists, then adding 10mL of a mixed solution of a solvent and a solvent into the rotary evaporation bottle, carrying out rotary evaporation again until no liquid exists, repeating the reaction for 2-3 times, finally adding 3mL of the mixed solution of the solvent and the solvent, transferring the solution to a 50mL centrifugal tube, adding 40mL of diethyl ether, placing the solution in a refrigerator at-20 ℃ for 20min, centrifuging, drying in vacuum, and weighing the crude peptide.
c. Preparation of teriparatide derivatives by liquid phase reaction
Weighing about 0.1mmol of dried crude peptide, about 0.095mmol of HOSU and sucking DIC15 μ L, adding about 5mL of tetrahydrofuran to dissolve in a 5mLEP tube, reacting at room temperature for 1-2 hours, transferring the reaction liquid to a 10mL rotary evaporation bottle, removing THF through rotary evaporation, adding about 5mLDMF into the rotary evaporation bottle, and dissolving the reaction product in the rotary evaporation bottle to obtain the side chain activated ester.
Then 0.5mmol of teriparatide analogue is dissolved in 0.1mol/L triethylamine solution, and side chain activated ester solution is slowly dripped into the solution, wherein the feeding ratio is 1: 1.2, stirred at room temperature for 10 minutes, after which the reaction was terminated by adjusting the pH to 8.0 with 0.1N hydrochloric acid.
The crude product was purified by semi-preparative RP-HPLC.
1 purification of
A chromatographic column: nano Micro C18 preparation column (10 mm. times.250 mm,10 μm)
Flow rate: 5ml/min
Detection wavelength: 215nm
Mobile phase: phase A: 1% HAC/water solution
Phase B: 1% HAC/acetonitrile
Gradient elution procedure as in table 3:
TABLE 3 gradient elution Table
Analysis of the collected product by Agilent 1260HPLC
A chromatographic column: YMC-pack ODS-AQ C18 analytical column (4.6 mm. times.250 mm,5 μm)
Flow rate: 1ml/min
Detection wavelength: 215nm
Mobile phase: phase A: 0.1% TFA/water
Phase B: 0.1% TFA/acetonitrile
Gradient elution procedure as in table 4:
TABLE 4 gradient elution Table
Collecting the target component with purity of more than 90%, low pressure rotary steaming, and freeze drying. The molecular weight is confirmed by ESI-MS, and M/Z is 1111.1 [ M +4H ]+Is consistent with the theoretical molecular weight.
Example 6: n-27-(Arg13,Arg26)PTH(1-34)-AEEA-Gly-AEEA-Gly-Glu-C17-COOH
(Arg13,Arg26)Lys27the-PTH (1-34) analogue is obtained by adopting an engineering bacteria expression or chemical synthesis method, wherein M/Z is 1044.3 [ M +4H ]+
Preparation of analogue derivatives molecular weight confirmation was carried out by ESI-MS as described in example 4, M/Z ═ 1251.8 [ M +4H ]+Is consistent with the theoretical molecular weight.
Example 7: n-26-(Cys13,Ala27)PTH(1-34)-Phe-AEEA-AEEA-AEEA-C12
(Cys13,Ala27)Lys26the-PTH (1-34) analogue is obtained by adopting an engineering bacteria expression or chemical synthesis method, wherein M/Z is 1009.7 [ M +4H ] +
The derivatives were prepared as described in example 4, and the molecular weight was confirmed by ESI-MS, M/Z-1200.7 [ M +4H ]+Is consistent with the theoretical molecular weight.
Example 8: n-26-(Arg13,Arg27)PTH(1-34)-AEEA-AEEA-C11-biotin
(Arg13,Arg27)Lys26the-PTH (1-34) analogue is obtained by adopting an engineering bacteria expression or chemical synthesis method, wherein M/Z is 1044.5 [ M +4H ]+
The derivatives were prepared as described in example 4, and the molecular weight was confirmed by ESI-MS, M/Z-1218.2 [ M +4H ]+Is consistent with the theoretical molecular weight.
Example 9: n-27-(Arg13,Arg26)PTH(1-34)-AEEA-AEEA-C17-COOH
(Arg13,Arg26)Lys27the-PTH (1-34) analogue is obtained by adopting an engineering bacteria expression or chemical synthesis method to obtain M/Z-1044.5 [ M +4H ]+
The derivatives were prepared as described in example 4, and the molecular weight was confirmed by ESI-MS, M/Z-1189.8 [ M +4H ]+Is consistent with the theoretical molecular weight.
Example 10: n-27-(Arg13,Arg26)PTH(1-34)-AEEA-Glu-C17-COOH
(Arg13,Arg26)Lys27Preparation of-PTH (1-34) analog using engineered bacteria expression or chemical synthesis to obtain M/Z ═ 1044.5 [ M +4H ] derivatives as described in example 4, molecular weight was confirmed by ESI-MS, M/Z ═ 1186.7 [ M +4H ]+Is consistent with the theoretical molecular weight.
Example 11: n-27-(Arg13,Arg26)PTH(1-34)-AEEA-AEEA-Ala-C17-COOH
(Arg13,Arg26)Lys27the-PTH (1-34) analogue is obtained by adopting an engineering bacteria expression or chemical synthesis method to obtain M/Z-1044.5 [ M +4H ]+The derivatives were prepared as described in example 4, and the molecular weight was confirmed by ESI-MS, M/Z-1208.5 [ M +4H ] +Is consistent with the theoretical molecular weight.
Example 12: n-27-(Arg13,Arg26)PTH(1-34)-AEEA-AEEA-C16
(Arg13,Arg26)Lys27the-PTH (1-34) analogue is obtained by adopting an engineering bacteria expression or chemical synthesis method to obtain M/Z-1044.5 [ M +4H ]+The derivatives were prepared as described in example 4, and the molecular weight was confirmed by ESI-MS, M/Z-1175.3 [ M +4H ]+Is consistent with the theoretical molecular weight.
Example 13: detection of in vitro active EC50
CHO-K1 cells were used, teriparatide acetate was used as a control, and the assay was performed according to the United states Pharmacopeia biological activity. In vitro cell activity assays were performed on PTH (1-34) and derivatives of PTH (1-34). Teriparatide is capable of specific binding to the cell surface PTH receptor (PTH1R), resulting in activation of adenylate cyclase and thus production of cyclic adenosine monophosphate (cAMP), which stimulates cellular metabolic pathways. The quantitative analysis of cAMP formed by PTH1-34 concentration-dependently in these cells was performed using time-resolved fluorescence technique (TR-FRET) (detection Kit: LANCEUltracAMP Kit from Perkinelmer). And analyzing experimental data by Prism5 software, fitting by using a four-parameter equation with the sample concentration as an X axis and the corresponding fluorescence ratio as a Y axis, and drawing a dose response curve of an active reference substance and a test substance to obtain an EC50 value.
Example 14: study of transmembrane transport of derivatives
Caco-2 cells were plated at 5X105Per cm2The density was measured by inoculating on the Apical side of a Millicell-CM insertion type cell culture dish (Transwell plate No. 3401, Corning Co.) with changing the solution every day, measuring the transmembrane resistance after the third week, and measuring the resistance when the resistance is more than 500. omega. CM2Can be used for transport experiments. Transport experiments on Caco-2 monolayers, teriparatide acetate (made by the laboratory) were used as a control. 0.3ml of PTH (1-34) or PTH (1-34) derivative solution (concentration 100. mu.g/ml) was added to the donor pool (AP-side), 0.7mg of Hank's buffer was added to the acceptor pool (BP-side), 0.1ml of the solution was taken out of the acceptor pool at various time points (0,20,45,60 and 90 minutes) and supplemented with an equal amount of blank Hank's solution, the concentration was measured using an ELISA kit and plotted against time using the apparent epithelial cell permeability coefficient PappIs calculated by formula
A is the area of the permeable membrane, here the donor cell membrane area (cm)2),C0Is the initial sample concentration (ng/ml) of the donor cell and dQ/dt is the diffusion flux (ng/s).
Teriparatide has high polarity and poor cell permeability, and cannot realize trans-cell transport. Surprisingly, the P of the modified teriparatide derivatives (examples 1 and 3) and the derivatives of teriparatide analogues (examples 5 and 7) appThe value is improved by 1.8-4 times, and according to the results of example 4 and example 8, the permeability of epithelial cell membranes is obviously improved after deoxycholic acid and biotin are modified, so that the transmembrane transport capacity of the polypeptide is enhanced, and a compound basis is effectively provided for polypeptide molecules to cross epithelial cell layers of gastrointestinal tracts.
While the compositions and methods of this invention have been described in terms of preferred embodiments in light of the present disclosure, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention.
The disclosures of all documents cited herein are incorporated by reference herein, to the extent that they provide exemplary, procedural and other details supplementary to those set forth herein.
Claims (10)
1. A teriparatide analogue characterized in that said analogue is modified and/or substituted with an amino acid at position 13, 26 and/or 27 of the N-terminus of teriparatide.
2. The teriparatide analogue according to claim 1, characterized in that the modification is an acylation modification at one, two or three of the lysines at position 13, 26 or 27 of the N-terminus of teriparatide.
3. A teriparatide analogue according to claim 2, characterised in that the modification for acylation is to link an aliphatic chain structure of the general formula: HOOC-(AEEA)m-(Xaa)n-R1Wherein Xaa is one or more of D-alanine, beta-alanine, 4-aminobutyric acid, 2-aminoisobutyric acid, 2-aminobutyric acid, arginine, aspartic acid, asparagine, cysteine, D-glutamic acid, gamma-glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, proline, phenylalanine, serine, tyrosine, threonine, tryptophan, valine and methionine or is absent; m is a number of 0,1,2,3,4, 5; n is one of 0,1,2 and 3; r1Selected from aliphatic straight chain and branched chain C6-C20Acyl group of deoxycholic acid, biotin or a deletion.
4. A teriparatide analogue according to any one of claims 1-3, characterised in that the analogue has a structure according to one of the following:
when two or three lysine modifications are present at position 13, 26 or 27, the T in the modifying group are of the same structure,
wherein, the chemical structural general formula T can be represented as:
wherein m is a number of 0,1,2,3,4,5, n is a number of 0,1,2,3, p is an integer of 6 to 20, R 2is-H or-COOH.
5. The teriparatide analogue of claim 1, wherein the analogue has a substitution of a lysine at position 13, 26 or 27 of the N-terminus of teriparatide, the analogue having the general formula:
H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-X1-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-X2-X3-Leu-Gln-Asp-Val-His-Asn-Phe-OH, wherein X1,X2,X3Not simultaneously Lys, and X1,X2,X3At least one of which is Lys, said teriparatide analogue having an acylation modification at a site located at X1,X2Or X3Lys of (a).
6. The teriparatide analogue according to claim 5, wherein the acylation modification is the attachment of an aliphatic chain structure of the general formula: HOOC- (AEEA)m-(Xaa)n-R1Wherein Xaa is one or more of D-alanine, beta-alanine, 4-aminobutyric acid, 2-aminoisobutyric acid, 2-aminobutyric acid, arginine, aspartic acid, asparagine, cysteine, D-glutamic acid, gamma-glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, proline, phenylalanine, serine, tyrosine, threonine, tryptophan, valine and methionine or is absent; m is a number of 0,1,2,3,4, 5; n is one of 0,1,2 and 3; r1Selected from aliphatic straight chain and branched chain C 6-C20Acyl group of deoxycholic acid, biotin or a deletion.
7. The teriparatide analogue according to claim 5, characterized in that the analogue has the structure as set forth in:
wherein, X1Selected from the group consisting of D-Ala, β -Ala, GABA, Aib, Abu, Arg, Asp, Asn, Cys, D-Glu, γ -Glu, Gln, Gly, His, Ile, Leu, Pro, Phe, Ser, Tyr, Thr, Trp, Val, Met, preferably β -Ala, GABA, Aib, Abu, Arg, Cys, more preferably Arg; x2Selected from D-Ala. beta-Ala, GABA, Aib, Abu, Arg, Asp, Asn, Cys, D-Glu, gamma-Glu, Gln, Gly, His, Ile, Leu, Pro, Phe, Ser, Tyr, Thr, Trp, Val, Met, preferably beta-Ala, GABA, Aib, Abu, Arg, Cys, more preferably Arg; x3Selected from the group consisting of D-Ala, β -Ala, GABA, Aib, Abu, Arg, Asp, Asn, Cys, D-Glu, γ -Glu, Gln, Gly, His, Ile, Leu, Pro, Phe, Ser, Tyr, Thr, Trp, Val, Met, preferably β -Ala, GABA, Aib, Abu, Arg, Cys, more preferably Arg;
wherein, the chemical structural general formula T can be represented as:
wherein m is a number of 0,1,2,3,4,5, n is a number of 0,1,2,3, p is an integer of 6 to 20, R2is-H or-COOH.
9. a pharmaceutical composition comprising a teriparatide analogue according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof.
10. The pharmaceutical composition according to claim 9, for use in the preparation of a medicament for the treatment of osteoporosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910362016 | 2019-04-30 | ||
CN201910362016X | 2019-04-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111848778A true CN111848778A (en) | 2020-10-30 |
CN111848778B CN111848778B (en) | 2024-03-19 |
Family
ID=72984965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010355587.3A Active CN111848778B (en) | 2019-04-30 | 2020-04-29 | Teriparatide analogues |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111848778B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024032457A1 (en) * | 2022-08-10 | 2024-02-15 | 成都奥达生物科技有限公司 | Long-acting teriparatide compound |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102731643A (en) * | 2012-06-26 | 2012-10-17 | 深圳翰宇药业股份有限公司 | Method for preparing polypeptide used for treating osteoporosis |
CN103467595A (en) * | 2013-09-06 | 2013-12-25 | 深圳翰宇药业股份有限公司 | Method for preparing teriparatide |
CN104017064A (en) * | 2014-06-13 | 2014-09-03 | 杭州诺泰制药技术有限公司 | Method for preparing teriparatide |
CN104910269A (en) * | 2015-06-02 | 2015-09-16 | 成都圣诺生物科技股份有限公司 | Method for synthesizing teriparatide |
CN107501408A (en) * | 2017-09-22 | 2017-12-22 | 扬子江药业集团四川海蓉药业有限公司 | A kind of preparation method of Teriparatide |
-
2020
- 2020-04-29 CN CN202010355587.3A patent/CN111848778B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102731643A (en) * | 2012-06-26 | 2012-10-17 | 深圳翰宇药业股份有限公司 | Method for preparing polypeptide used for treating osteoporosis |
CN103467595A (en) * | 2013-09-06 | 2013-12-25 | 深圳翰宇药业股份有限公司 | Method for preparing teriparatide |
CN104017064A (en) * | 2014-06-13 | 2014-09-03 | 杭州诺泰制药技术有限公司 | Method for preparing teriparatide |
CN104910269A (en) * | 2015-06-02 | 2015-09-16 | 成都圣诺生物科技股份有限公司 | Method for synthesizing teriparatide |
CN107501408A (en) * | 2017-09-22 | 2017-12-22 | 扬子江药业集团四川海蓉药业有限公司 | A kind of preparation method of Teriparatide |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024032457A1 (en) * | 2022-08-10 | 2024-02-15 | 成都奥达生物科技有限公司 | Long-acting teriparatide compound |
Also Published As
Publication number | Publication date |
---|---|
CN111848778B (en) | 2024-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9868766B2 (en) | Peptides as oxytocin agonists | |
JP2795449B2 (en) | Therapeutic peptides | |
JP2919889B2 (en) | Therapeutic peptides | |
US4935492A (en) | Cyclic analogs of atrial natriuretic peptides | |
US20140162943A1 (en) | N-terminus conformationally constrained glp-1 receptor agonist compounds | |
NO302619B1 (en) | Analogous Process for Preparing a Therapeutic Peptide | |
JP6164556B2 (en) | Drug for producing radiolabeled polypeptide with reduced nonspecific renal accumulation | |
JP6535688B2 (en) | Peptide as an oxytocin agonist | |
EP0270376A2 (en) | Calcitonin gene-related peptide derivatives | |
CN111848778B (en) | Teriparatide analogues | |
US9957298B2 (en) | Peptides as oxytocin agonists | |
JP2012524775A (en) | Short peptides as parathyroid hormone (PTH) receptor agonists | |
EP0585444B1 (en) | Hepatoma treatment with somatostatin analogs | |
US6083915A (en) | Method for treating liver cancer | |
WO1993017701A1 (en) | Endothelin receptor-binding peptides | |
CN116333092A (en) | Teriparatide lipidated derivatives | |
CN116685599A (en) | Polypeptides and uses thereof | |
Spear et al. | Analogs of atriopeptin (103-125) amide having high binding selectivity | |
JP7434616B2 (en) | Prodrugs and their use | |
CN113164613B (en) | Method for optimizing dimeric peptide-phospholipid conjugates | |
Abiko et al. | Syntheses of two neuromedin U (NMU) analogues and their comparative reducing food intake effect in rats | |
US11332498B2 (en) | Ligands for integrin αVβ8, synthesis and uses thereof | |
CN101223189A (en) | Novel compounds as GLP-I agonists | |
JPS61227595A (en) | Aromatic basic terminal vasopressin antagonist | |
CN114957443A (en) | GLP-1 analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |